Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure.

Clicks: 143
ID: 280531
2023
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #36 of 39 articles by views in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The impact of body mass index (BMI) on treatment outcomes in patients with cancer is gaining increasing attention given the limited data available. The aim of this study was to investigate the contribution of BMI on the safety and efficacy profile of palbociclib in 134 patients with metastatic luminal-like breast cancer treated with palbociclib and endocrine therapy (ET). Normal-weight and underweight patients (BMI<25) were compared with overweight and obese (BMI≥25). Detailed clinical and demographic data were collected. Patients with a BMI<25 had a higher incidence of relevant-hematologic toxicities (p = 0.001), dose reduction events (p = 0.003), and tolerated lower dose intensities (p = 0.023) compared to patients with a BMI≥25. In addition, patients with a BMI<25 had significantly shorter progression-free survival (log-rank p = 0.0332). A significant difference was observed in the subgroup of patients for whom systemic palbociclib concentrations were available: patients with a BMI<25 had a 25% higher median minimum plasma concentrations (C) compared to BMI≥25. This study provides compelling evidence for a clinically relevant contribution of BMI in discriminating a group of patients who experienced multiple toxicities that appeared to affect treatment adherence and lead to poorer survival. BMI could become a valuable tool for personalizing the starting dose of palbociclib to improve its safety and efficacy.
Reference Key
roncato2023clinicalbiomedicine Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Roncato, Rossana;Peruzzi, Elena;Gerratana, Lorenzo;Posocco, Bianca;Nuzzo, Sofia;Montico, Marcella;Orleni, Marco;Corsetti, Serena;Bartoletti, Michele;Gagno, Sara;Canil, Giovanni;De Mattia, Elena;Angelini, Jacopo;Baraldo, Massimo;Puglisi, Fabio;Cecchin, Erika;Toffoli, Giuseppe;
Journal Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Year 2023
DOI
10.1016/j.biopha.2023.114906
URL
Keywords
body mass index treatment adherence palbociclib her-negative breast cancer hormon receptor-positive progression free survival

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.